TABLE 3.
Tumor sizes, response to therapy, and follow-up events
| Case # | Initial tumor size in cm | Final tumor size in cm | Autoimmune toxicities | Pathologic response to therapy | Follow-up therapies | Posttreatment relapse | Recurrence-free survival in months (location of recurrence) | Current status | Overall survival in months |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 6.5 | 8.4 | Hypothyroidism | Progression | Nivolumab and eribulin | Had continued progression on therapy | 0 | Deceased | 6 |
| 2 | 3.4 | 4 | None | Partial response, RCB-II (ypT2 pN0) | Capecitabine | No | 29+ | Alive | 29+ |
| 3 | 1.5 | 0.8 | Hypothyroidism | Pathological complete response | Capecitabine | No | 33+ | Alive | 33+ |
| 4 | 3 | 2.2 | None | Partial response, RCB-III (ypT2 pN1a) | ddAC and capecitabine, gencitabine and carbotaxol, tucatinib/ trastuzumab, sacituzumab | Yes | 17 (brain metastases) | Deceased | 23 |
| 5 | 3.3 | 2.3 | None | Partial response, RCB-II (rypT1a pN1a) | none | Yes | 13 (nodal metastasis) | Alive | 19+ |
| 6 | 6.1 | 3.9 | Hypothyroidism, rash, T1DM | Partial response, RCB-II (ypT1a pN0) | none | No | 17+ | Alive | 17+ |